The study product, Ovaprene®, is an experimental monthly non-hormonal intravaginal contraceptive ring being developed as a possible new method of birth control.

This study is being conducted to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. We are hoping to find out if genetic differences impact the risk of emergency contraceptive failure. The drug used in this study is the FDA approved oral emergency contraceptive pill containing ulipristal acetate (UPA, otherwise known as Ella©). The overall goal of this research is to improve the effectiveness of emergency contraceptive pills for all people. The study will test to see how well the drug (UPA) works on the ovary as well as to gather more information in women of varying race and ethnicity.

The purpose of the study is to learn more about a medication called Tranexamic Acid (Otherwise known as Lysteda; TXA-for short) that may be helpful in decreasing vaginal bleeding that individuals can have when using the contraceptive implant (Nexplanon). The medications used in this study is the FDA-approved drug called Tranexamic acid.

The purpose of this study is to develop a better understanding of why some people who use progestin-only contraception, such as the contraceptive implant (Nexplanon) or contraceptive injectable (Depo-Provera), have changes to their menstrual bleeding patterns. We are hoping to find out what changes in the endometrium (the lining tissue of the uterus) lead to different bleeding patterns during the first year of progestin contraception use.